Brokerages Anticipate Invivo Therapeutics Holdings Corp (NVIV) Will Announce Earnings of -$0.16 Per Share

Brokerages forecast that Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) will announce earnings of ($0.16) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Invivo Therapeutics’ earnings. Invivo Therapeutics posted earnings per share of ($0.21) during the same quarter last year, which suggests a positive year over year growth rate of 23.8%. The business is expected to report its next quarterly earnings report on Friday, March 9th.

According to Zacks, analysts expect that Invivo Therapeutics will report full year earnings of ($0.81) per share for the current financial year, with EPS estimates ranging from ($0.83) to ($0.79). For the next year, analysts expect that the company will post earnings of ($0.74) per share, with EPS estimates ranging from ($0.87) to ($0.61). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that follow Invivo Therapeutics.

Shares of Invivo Therapeutics (NASDAQ:NVIV) traded down $0.05 during midday trading on Friday, hitting $0.48. 298,051 shares of the company’s stock were exchanged, compared to its average volume of 312,654. Invivo Therapeutics has a fifty-two week low of $0.45 and a fifty-two week high of $4.60. The company has a market capitalization of $17.80, a P/E ratio of -0.56 and a beta of 2.71. The company has a quick ratio of 5.06, a current ratio of 5.06 and a debt-to-equity ratio of 0.04.

A hedge fund recently bought a new stake in Invivo Therapeutics stock. Susquehanna International Group LLP purchased a new stake in shares of Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 160,740 shares of the biotechnology company’s stock, valued at approximately $434,000. Susquehanna International Group LLP owned approximately 0.50% of Invivo Therapeutics as of its most recent SEC filing. Institutional investors own 12.03% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This article was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at

About Invivo Therapeutics

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc, is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury.

Get a free copy of the Zacks research report on Invivo Therapeutics (NVIV)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Invivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivo Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply